Estimating the relative risk of developing melanoma in INK4A carriers. Academic Article uri icon

Overview

abstract

  • Estimation of the relative risk of cancer due to rare germline mutations using population-based epidemiological techniques is challenging, since studies with very large numbers of subjects are required. In this pilot study using a novel study design, we evaluated the role of INK4A mutations in melanoma by comparing patients with multiple primary melanomas to those with single primaries. Patients were ascertained from the Surgery and Dermatology Clinics at Memorial Sloan-Kettering Cancer Center and at the Yale University Pigmented Lesion Clinic. Subjects completed a questionnaire covering risk factors for melanoma and were tested for INK4A mutations. Five (8%) of 65 patients with multiple primaries had a mutation, compared with none of 88 patients with single primaries (P=0.03). Examination of other factors, such as number of nevi on the arms of the patients, fair skin, hair and eye colour, and other phenotypic characteristics associated with the risk of melanoma, demonstrates that these factors exhibit higher prevalence in the multiple primary cases than in the single primaries. These results provide evidence of the utility of the new study design in evaluating the impact of rare but highly penetrant cancer risk factors.

publication date

  • February 1, 2004

Research

keywords

  • Cyclin-Dependent Kinase Inhibitor p16
  • Melanoma
  • Neoplasms, Multiple Primary
  • Skin Neoplasms

Identity

Scopus Document Identifier

  • 12144288315

Digital Object Identifier (DOI)

  • 10.1097/00008469-200402000-00010

PubMed ID

  • 15075790

Additional Document Info

volume

  • 13

issue

  • 1